News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EffRx and Nycomed Announces First European Filing for Marketing Approval of Osteoporosis Drug Targeting Increased Convenience for Patients


9/21/2010 10:34:17 AM

LAUSANNE, Switzerland--(BUSINESS WIRE)--The Lausanne, Switzerland, based drug delivery company EffRx Pharmaceuticals SA (“EffRx”) and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.

Read at BioSpace.com


comments powered by Disqus
Nycomed
EffRx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES